

Application No. 10/018,189

AMENDMENTS TO THE CLAIMS

A detailed listing of all claims that are, or were, in the present application, irrespective of whether the claim(s) remains under examination in the application are presented below. The claims are presented in ascending order and each includes one status identifier. Those claims not cancelled or withdrawn but amended by the current amendment utilize the following notations for amendment: 1. deleted matter is shown by strikethrough for six or more characters and double brackets for five or less characters; and 2. added matter is shown by underlining.

1-5. (Withdrawn)

6. (Canceled)

13. (Currently Amended) A method ~~of preventing or treating insulin resistance in a human or non-human animal suffering therefrom,~~ for potentiating normal or deficient insulin function on glucose metabolism in a mammal when measured on an intravenous glucose tolerance test, said method comprising the administration of an effective amount of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids.

14-15. (Withdrawn)

16. (Currently Amended) A method, as defined in claim 13, wherein said one or more compounds is administered ~~of preventing or treating insulin resistance in a human or non-human animal comprising the consumption of one or more compounds selected from the group consisting of fish protein, hydrolysed fish protein and fish protein amino acids in a quantity that is about 4% to about 60% of said animal's~~ the mammal's diet.

17-18. (Withdrawn)

Application No. 10/018,189

19. (Currently Amended) A method as defined in claim 13, wherein said deficient insulin function is caused by resistance or hyperglycemia is the result of Type 1 or Type 2 diabetes.

20. (Currently Amended) A method as defined in claim 13, wherein said fish protein is cod [[fish]] protein.

21. (Previously Presented) A method as defined in claim 20, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

22-25. (Withdrawn)

26. (Currently Amended) A method, as defined in claim 13, wherein said of preventing or treating insulin resistance in a human or non-human animal suffering therefrom, comprising the administration of an effective amount of a mixture of one or more amino acids comprise [[in]] the following weight proportion (units of amino acid/100 units of total amino acids): about 6.74 alanine per 100 units of total amino acids; about 6.29 arginine per 100 units of total amino acids; about 11.14 aspartic acid per 100 units of total amino acids; about 16.75 glutamic acid per 100 units of total amino acids; about 5.39 glycine per 100 units of total amino acids; about 2.27 histidine per 100 units of total amino acids; about 3.24 isoleucine per 100 units of total amino acids; about 8.31 leucin per 100 units of total amino acids; about 1.98 methionine per 100 units of total amino acids; about 9.41 lysine per 100 units of total amino acids; about 4.22 phenylalanine per 100 units of total amino acids; about 4.42 proline per 100 units of total amino acids; about 5.55 serine per 100 units of total amino acids; about 4.84 threonine per 100 units of total amino acids; about 4.31 tyrosine per 100 units of total amino acids; and about 3.86 valine per 100 units of total amino acids.

27-28. (Withdrawn)

29. (Currently Amended) A method as defined in claim 26, wherein said deficient insulin resistance function is caused by [[or]] hyperglycemia is the result of Type 1 or Type 2 diabetes.

Application No. 10/018,189

30. (Previously Presented) A method as defined in claim 29, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

31-40. (Withdrawn)

41. (Currently Amended) A method as defined in claim ~~[[16]]~~ 13, wherein said ~~insulin~~ resistance or hyperglycemia is the result of Type 1 or Type 2 diabetes.

42-44. (Withdrawn)

45. (Currently Amended) A method as defined in claim ~~[[16]]~~ 29, wherein said ~~fish protein is~~ cod fish wherein said hyperglycemia is the result of Type 1 or Type 2 diabetes.

46-47. (Withdrawn)

48. (Currently Amended) A method as defined in claim 19, wherein said fish protein is ~~cod~~ [[fish]] protein.

50. (Currently Amended) A method as defined in claim 41, wherein said fish protein is ~~cod~~ [[fish]] protein.

51-64. (Withdrawn)

65. (Previously Presented) A method as defined in claim 45, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

66-67. (Withdrawn)

Application No. 10/018,189

68. (Previously Presented) A method as defined in claim 48, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

69. (Withdrawn)

70. (Previously Presented) A method as defined in claim 50, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

71. (Withdrawn)

Please add the following new claim:

72. (New) A method, as defined in claim 13, wherein said deficient insulin function is caused by obesity.